These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 38653946)
1. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma. Zhang X; Wang W; Mo S; Sun X Dig Dis Sci; 2024 Jun; 69(6):2096-2108. PubMed ID: 38653946 [TBL] [Abstract][Full Text] [Related]
2. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. Fu X; Liu M; Qu S; Ma J; Zhang Y; Shi T; Wen H; Yang Y; Wang S; Wang J; Nan K; Yao Y; Tian T J Exp Clin Cancer Res; 2018 Mar; 37(1):52. PubMed ID: 29530052 [TBL] [Abstract][Full Text] [Related]
3. CircDDX17 reduces 5-fluorouracil resistance and hinders tumorigenesis in colorectal cancer by regulating miR-31-5p/KANK1 axis. Ren TJ; Liu C; Hou JF; Shan FX Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1743-1754. PubMed ID: 32141542 [TBL] [Abstract][Full Text] [Related]
4. Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway. Li X; Yin X; Bao H; Liu C Mol Cell Probes; 2023 Feb; 67():101877. PubMed ID: 36442661 [TBL] [Abstract][Full Text] [Related]
5. CircMTO1 suppresses hepatocellular carcinoma progression via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling pathway and epithelial-to-mesenchymal transition. Li D; Zhang J; Yang J; Wang J; Zhang R; Li J; Zhang R Cell Death Dis; 2021 Dec; 13(1):12. PubMed ID: 34930906 [TBL] [Abstract][Full Text] [Related]
6. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944 [TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399 [TBL] [Abstract][Full Text] [Related]
9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
10. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway. Bao Y; Xu S; Zhou J; Zhao C; Dai S; Zhang Y; Rao M J Biochem Mol Toxicol; 2024 Mar; 38(3):e23666. PubMed ID: 38375688 [TBL] [Abstract][Full Text] [Related]
11. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway. Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514 [No Abstract] [Full Text] [Related]
12. MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1. Guo XL; Wang HB; Yong JK; Zhong J; Li QH Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6667-6677. PubMed ID: 30402839 [TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. Gao J; Dai C; Yu X; Yin XB; Zhou F J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108 [TBL] [Abstract][Full Text] [Related]
14. N Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway. Li WF; Dai H; Ou Q; Zuo GQ; Liu CA Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417 [TBL] [Abstract][Full Text] [Related]
16. Circ_0004018 suppresses cell proliferation and migration in hepatocellular carcinoma via miR-1197/PTEN/PI3K/AKT signaling pathway. Wang H; Zhang Q; Cui W; Li W; Zhang J Cell Cycle; 2021 Oct; 20(20):2125-2136. PubMed ID: 34570663 [TBL] [Abstract][Full Text] [Related]
17. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326 [TBL] [Abstract][Full Text] [Related]
18. CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway. Zheng SS; Wu JF; Wu WX; Hu JW; Zhang D; Huang C; Zhang BH Hepatol Int; 2024 Oct; 18(5):1499-1515. PubMed ID: 38769286 [TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970 [TBL] [Abstract][Full Text] [Related]
20. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p. Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]